Press Release: Sweet Earth Announces Letter Of Intent To Partner With Vesalius Labs

Sweet Earth and Vesalius Longevity Labs Announce Transformative Business Combination

March 4, 2025 – Vancouver, BC – Vesalius Longevity Labs is excited to announce a game-changing merger with Sweet Earth Holdings Corporation (CSE: SE) (FSE: 1KZ1) (OTCQB: SEHCF). This partnership represents a major milestone in our mission to advance the science of longevity and revolutionize human health.

Under a binding Letter of Intent (LOI) signed on February 27, 2025, Sweet Earth, Vesalius Longevity Labs (Canada) Inc., and Vesalius Longevity Labs (SPV) Inc. will combine their businesses through a reverse takeover (RTO), subject to final agreements and regulatory approvals. The newly formed entity, to be named Vesalius Longevity Labs, will become a global leader in cutting-edge peptide and longevity solutions.

A New Era for Longevity Science

This transaction aligns with Vesalius' commitment to pioneering innovations in regenerative medicine, biotechnology, and peptide therapies. With an extensive network of doctors and health professionals, Vesalius is poised to lead the charge in extending human healthspan through advanced, science-backed solutions.

Upon completion, Vesalius and SPV shareholders will hold approximately 82.5% of the newly formed company's shares. Additionally, the transaction includes a $10 million private placement financing, further reinforcing our growth trajectory.

Meet the Leadership Team

The newly structured company will feature an exceptional leadership team and board, including influential figures in biotech, finance, and global investment.

Key management executives include:

• Kevin Rabbitt – CEO
• Christopher R. Cooper – CFO & Corporate Secretary
• Timmi Stump – Chief Commercial Officer
• Shannon Louden – Chief Product Officer

The board of directors will include:

• Kevin Rabbitt
• HRH Prince Khaled bin Alwaleed Al Saud
• Ahmed Alkhoshaibi
• Mark Patricof
• Joel Leonoff
• Richard Serbin
• Bob McCue

Scientific & Strategic Advisors

Vesalius is proud to have assembled a world-class advisory team to drive innovation in longevity science and human performance. Key advisors include:

Special Advisory Board:

• Gary Brecka – Human biologist & longevity expert
• Ben Greenfield – Health & wellness entrepreneur
• Chris Bumstead (Cbum) – 6x Classic Physique Mr. Olympia & fitness icon
• George Kittle – NFL superstar & entrepreneur

Scientific Advisory Board:

• Dr. Matt Cook – Regenerative medicine specialist
• Dr. Jonathan Kuo – Anti-aging medicine expert
• Dr. Melissa Peterson – Founder, Human Longevity Institute
• Dr. Chris Renna – Founder, LifeSpan Medicine
• Dr. Kevin Serre – Human performance consultant

A Vision for the Future

“This merger is a transformational moment for Vesalius. Our mission is clear: harness cutting-edge biotech innovations to empower people to live longer, healthier lives. We are thrilled to accelerate our growth and expand our global reach.” – Kevin Rabbitt, CEO & Founder

“Vesalius is uniquely positioned at the forefront of the peptide revolution. This partnership allows us to lead the industry with integrity, transparency, and science-backed innovation.” – Gary Brecka, Strategic Advisor & Founder

What’s Next?

With new capital investment, world-class leadership, and a growing market for longevity solutions, Vesalius is well-positioned to redefine human health. Over the coming months, we will finalize regulatory approvals, complete financing rounds, and execute our vision to bring next-generation longevity solutions to millions worldwide.

Stay tuned for more updates as we embark on this exciting journey to redefine the future of human health!